Travere (TVTX) Q4 2025 Earnings Transcript

Travere reported a strong Q4 with U.S. net product sales of $126.6 million, up 144% year over year for FILSPARI, and full-year net product sales of $410.5 million, while Q4 net income turned positive at $2.7 million versus a $60.3 million loss a year ago. Management also confirmed the FDA set an April 13, 2026 PDUFA date for FILSPARI in FSGS and said it expects continued growth, with 2026 FILSPARI gross-to-net discounts rising to the mid-20%s from about 20% at year-end 2025. The company ended with $322.8 million in cash and said it does not anticipate near-term capital needs.

Analysis

TVTX is transitioning from a single-product launch story into a multi-catalyst rerating case, but the market is still underappreciating how much of the next 6 months is de-risked by commercial execution rather than binary FDA speculation. The key second-order effect is that broad payer access plus earlier-stage prescribing expands the addressable pool faster than simple share capture would suggest; the company is effectively teaching the market to treat IgAN as a chronic branded market, not a one-off specialty script event.

The bigger strategic implication is competitive: an FSGS label would not just add revenue, it would create a halo that lowers physician friction in IgAN and compresses sales-cycle length across overlapping nephrology accounts. That matters because the field force expansion is already in place; approval would turn fixed commercial spend into incremental operating leverage, while a delay or CRL would leave the company carrying a larger cost base into 2026 and likely force a reset in growth expectations.

The main risk is that consensus is extrapolating start-form momentum too linearly into revenue without fully modeling the first-quarter gross-to-net step-up and the possibility of slower persistence as competition broadens. A more subtle risk is that the FDA’s insistence on “clinical benefit” language could be a signal that the agency wants a tighter evidentiary bridge than management is implying, even if it does not explicitly reject proteinuria as a surrogate. That makes the next 7 weeks more about label quality and commercial optionality than about the already-strong IgAN run-rate.

Contrarian read: the stock may still be cheap if the market is assigning low probability to FSGS approval and a modest peak-share outcome in IgAN. But the cleaner trade is not to chase outright into the PDUFA; it is to own the optionality while hedging the event risk, because the valuation reaction to an approval should be amplified by the implied halo effect and by the company’s ability to deploy a fully built field force immediately.

Key Decisions for Investors

• Long TVTX common into the April 13 FSGS PDUFA with a 4-8 week horizon; catalyst skew is favorable, but size at 50-60% of target because a delay or label disappointment could compress the stock 20-30% quickly.
• Prefer a call spread over outright stock: buy TVTX May/Jun 2026 calls and sell a higher strike against them to monetize the binary event while limiting theta bleed if approval lands on time.
• If already long TVTX, hedge the event with short-dated puts into the quiet period/decision window; the gross-to-net reset can obscure underlying demand and create a sharp post-event shakeout even on a positive headline.
• Relative-value: long TVTX / short NVS over the next 1-3 months as a cleaner way to express FSGS-approval upside versus pressure on a competitive IgAN entrant with less embedded FSGS optionality.
• For more risk-averse capital, wait for either an FDA decision or a post-PDUFA selloff; if approval hits and the stock overreacts lower on guidance conservatism, use that as the better entry point for a 6-12 month hold.